Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ianalumab versus placebo in combination with eltrombopag for steroid-refractory or relapsed first-line primary ITP
CTR20230553Phase 3Active
- Sponsor
- Novartis
- Start
- May 2023
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ianalumab, eltrombopag in immune thrombocytopenia (ITP), sponsored by Novartis. Started May 2023; status: active.
02
Drugs
ianalumabeltrombopag
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on CTR20230553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230553.